JNJ · Forward model · MedTech Vision
What has to happen in MedTech Vision
Model as of
This page changes MedTech Vision inside the complete JNJ model. Every other vertical, corporate programme and valuation assumption stays in the selected portfolio case.
Shares this vertical and portfolio case. Slider and horizon edits stay in your browser.
MedTech Vision
Basis quarter$1.45B
Final quarter$1.82B
Implied CAGR+5%
Final revenue mix5%
ACUVUE contact lenses plus surgical vision - the most consumer-like, most currency-exposed MedTech line.
Last four quarters
2025 Q3
$1.40B
Reported
2025 Q4
$1.42B
Reported
2026 Q1
$1.36B
Reported
2026 Q2
$1.45B
Reported
Contact lenses and otherSurgical vision
Sequential growth
+1.3%/qtr
decaying toward +1.0%
1.3% a quarter against +6.0% year over year; ACUVUE price and mix, since no unit disclosure exists.
MedTech Vision
Latest: $1.82B (2031Q2E)
| Period | Value |
|---|---|
| 2023Q1 | $1.30B |
| 2023Q2 | $1.31B |
| 2023Q3 | $1.26B |
| 2023Q4 | $1.21B |
| 2024Q1 | $1.26B |
| 2024Q2 | $1.28B |
| 2024Q3 | $1.30B |
| 2024Q4 | $1.30B |
| 2025Q1 | $1.28B |
| 2025Q2 | $1.37B |
| 2025Q3 | $1.40B |
| 2025Q4 | $1.42B |
| 2026Q1 | $1.36B |
| 2026Q2 | $1.45B |
| 2026Q3E | $1.47B |
| 2026Q4E | $1.49B |
| 2027Q1E | $1.51B |
| 2027Q2E | $1.53B |
| 2027Q3E | $1.54B |
| 2027Q4E | $1.56B |
| 2028Q1E | $1.58B |
| 2028Q2E | $1.60B |
| 2028Q3E | $1.62B |
| 2028Q4E | $1.63B |
| 2029Q1E | $1.65B |
| 2029Q2E | $1.67B |
| 2029Q3E | $1.69B |
| 2029Q4E | $1.71B |
| 2030Q1E | $1.72B |
| 2030Q2E | $1.74B |
| 2030Q3E | $1.76B |
| 2030Q4E | $1.78B |
| 2031Q1E | $1.80B |
| 2031Q2E | $1.82B |
Assumptions & reasoning
- ACUVUE contact lenses plus surgical vision, the most consumer-like and most currency-exposed MedTech line, growing +6.0% year over year and +7.3% on a trailing-twelve-month basis.
- Left aseasonal: the 2.7% amplitude is well inside a 5.2% worst-quarter window spread, so any shape asserted here would be noise.